Clinical Trial Update: Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment [Phase 1]

View source ↗

Summary

A Phase 1 single-dose safety study of a compound to treat anemia in patients with renal impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Compound

Snippet

Sponsor: GlaxoSmithKline | Conditions: Kidney Disease | Phase 1 | Status: COMPLETED